NCT03760614View on ClinicalTrials.gov

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 31, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

November 30, 2022

Conditions

Pancreas Cancer

Interventions

DRUG

Entinostat

Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.

DRUG

FOLFOX regimen

FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.

Sponsors

Collaborators (1)

Syndax Pharmaceuticals

All Listed Sponsors

collaborator

Syndax Pharmaceuticals

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER